Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 21 April 2005. doi:10.1136/hrt.2005.064501
Heart 2006;92:49-51
Copyright © 2006 BMJ Publishing Group Ltd & British Cardiovascular Society

CARDIOVASCULAR MEDICINE

Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment

D Mukherjee1, E J Topol2, D J Moliterno1, D M Brennan2, K Ziada1, L Cho3, S R Steinhubl1 for the CREDO Investigators

1 Division of Cardiovascular Medicine and the Gill Heart Institute, Lexington, Kentucky, USA
2 Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
3 Division of Cardiology, Loyola University Medical Center, Chicago, Illinois, USA

Correspondence to:
Dr Debabrata Mukherjee
Gill Heart Institute, Division of Cardiovascular Medicine, University of Kentucky, 900 S Limestone Street, 326 Wethington Building, Lexington, Kentucky 40536-0200, USA; Mukherjee{at}uky.edu

Objective: To assess the effectiveness of long term treatment with clopidogrel of patients with extracardiac vascular disease (ECVD) (a history of either peripheral arterial disease or cerebrovascular disease).

Design: Subgroup analysis of a prospective randomised clinical trial.

Setting: The CREDO (clopidogrel for the reduction of events during observation) trial was a randomised, double blind, placebo controlled trial conducted at 99 centres in North America from June 1999 through April 2001.

Patients: 2116 patients who were to undergo elective coronary intervention or were deemed at high likelihood of undergoing percutaneous coronary intervention were enrolled in the CREDO trial. The current study sample consisted of 272 patients with ECVD.

Main outcome measure: One year incidence of the composite of death, myocardial infarction, or stroke in the intent to treat population.

Results: Patients with ECVD had a more than twofold greater relative risk reduction with clopidogrel for the primary end point compared with patients without ECVD (47.9%, 95% confidence interval (CI) –4.2% to 73.9%, v 18.2%, 95% CI –10.5 % to 39.5%, respectively).

Conclusions: Longer term clopidogrel treatment provides added protection against thrombotic events throughout the arterial vasculature, not limited to the coronary arteries, and may be especially effective for patients with more diffuse atherosclerosis such as ECVD.

Abbreviations: CI, confidence interval; CREDO, clopidogrel for the reduction of events during observation; ECVD, extracardiac vascular disease; PCI, percutaneous coronary intervention

Keywords: peripheral arterial disease; clopidogrel; vascular disease; antiplatelet treatment


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Antiplatelet therapy and the vascular tree
A Blann
Heart 2006 92: 3-4. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Hackam, D G, Sultan, N M, Criqui, M H (2009). Vascular protection in peripheral artery disease: systematic review and modelling study. Heart 95: 1098-1102 [Abstract] [Full Text]  
  • Hackam, D. G, Eikelboom, J. W (2007). Antithrombotic treatment for peripheral arterial disease. Heart 93: 303-308 [Abstract] [Full Text]  
  • Blann, A (2006). Antiplatelet therapy and the vascular tree. Heart 92: 3-4 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.